0000000001313279

AUTHOR

F. Huber

showing 5 related works from this author

Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

2020

Abstract Background High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. Methods A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed …

Male0301 basic medicinePsychological interventionHuman immunodeficiency virus (HIV)MedizinContinuum of care; Europe; HIV infection; Key population; Sex; Anti-Retroviral Agents; Continuity of Patient Care; European Union; HIV; Humans; Male; HIV InfectionsHIV InfectionsContinuum of care; Europe; HIV infection; Key population; Sexmedicine.disease_causekey population0302 clinical medicineContinuum of careHIV Infection030212 general & internal medicineMen having sex with menContinuum of caremedia_commoneducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTransmission (medicine)Continuity of Patient CareEuropeInfectious DiseasesAcademicSubjects/MED00290Anti-Retroviral AgentsHIV infection continuum of care sex key population EuropeSexMicrobiology (medical)PopulationSocio-culturale03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationPandemicsHIV infection ; continuum of care ; sex ; key population ; Europebusiness.industrySARS-CoV-2COVID-19HIVmedicine.diseaseHIV infectioncontinuum of care030112 virologyMajor Articles and CommentariesKey populationAnti-Retroviral Agentbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemography
researchProduct

AKI - human studies

2013

03 medical and health sciencesTransplantationmedicine.medical_specialty0302 clinical medicineHuman studiesNephrologybusiness.industry030232 urology & nephrologyMedicine030204 cardiovascular system & hematologybusinessIntensive care medicineNephrology Dialysis Transplantation
researchProduct

CCDC 114783: Experimental Crystal Structure Determination

2000

Related Article: M.Schurmann, R.Schmiedgen, F.Huber, A.Silvestri, G.Ruisi, A.B.Paulsen, R.Barbieri|1999|J.Organomet.Chem.|584|103|doi:10.1016/S0022-328X(99)00103-5

Space GroupCrystallography(4-Chlorophenyl)-tris(quinolin-8-olato-NO)-tin(iv) chloroform solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 158238: Experimental Crystal Structure Determination

2001

Related Article: M.Schurmann, F.Huber, R.Barbieri|2001|Acta Crystallogr.,Sect.C:Cryst.Struct.Commun.|57|40|doi:10.1107/S0108270100015146

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(2-Chlorobenzyl)-tris(2-pyridinethiolato)-tin(iv)Experimental 3D Coordinates
researchProduct

CCDC 115540: Experimental Crystal Structure Determination

2000

Related Article: M.Schurmann, A.Silvestri, G.Ruisi, M.A.Girasolo, A.B.Paulsen, F.Huber, R.Barbieri|1999|J.Organomet.Chem.|584|293|doi:10.1016/S0022-328X(99)00166-7

Space GroupCrystallographytetrakis(2-Chlorobenzyl)-tin(iv)Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct